BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36194351)

  • 21. Pan-Trk Immunohistochemistry Is an Efficient and Reliable Screen for the Detection of NTRK Fusions.
    Hechtman JF; Benayed R; Hyman DM; Drilon A; Zehir A; Frosina D; Arcila ME; Dogan S; Klimstra DS; Ladanyi M; Jungbluth AA
    Am J Surg Pathol; 2017 Nov; 41(11):1547-1551. PubMed ID: 28719467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [NTRK Fusions: A new way of treatment for gastro-intestinal tumor?].
    Ouali K; Pellat A; Cohen R; Svrcek M; Penault-Llorca F; André T
    Bull Cancer; 2020 Apr; 107(4):447-457. PubMed ID: 32067719
    [TBL] [Abstract][Full Text] [Related]  

  • 23. NTRK gene fusion testing and management in lung cancer.
    Repetto M; Chiara Garassino M; Loong HH; Lopez-Rios F; Mok T; Peters S; Planchard D; Popat S; Rudzinski ER; Drilon A; Zhou C
    Cancer Treat Rev; 2024 Jun; 127():102733. PubMed ID: 38733648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recommended testing algorithms for NTRK gene fusions in pediatric and selected adult cancers: Consensus of a Singapore Task Force.
    Lim KHT; Kong HL; Chang KTE; Tan DSW; Tan IBH; Mohamad F; Soh SY; Pang BN; Soo RA; Choo SP; Hsieh WS; Aung L
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):394-403. PubMed ID: 34806337
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A systematic comparison of pan-Trk immunohistochemistry assays among multiple cancer types.
    Haberecker M; Töpfer A; Melega F; Moch H; Pauli C
    Histopathology; 2023 Jun; 82(7):1003-1012. PubMed ID: 36759438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficient Identification of Patients With NTRK Fusions Using a Supervised Tumor-Agnostic Approach.
    Hernandez S; Conde E; Molero A; Suarez-Gauthier A; Martinez R; Alonso M; Plaza C; Camacho C; Chantada D; Juaneda-Magdalena L; Garcia-Toro E; Saiz-Lopez P; Rojo F; Abad M; Boni V; Del Carmen S; Regojo RM; Sanchez-Frias ME; Teixido C; Paz-Ares L; Lopez-Rios F
    Arch Pathol Lab Med; 2024 Mar; 148(3):318-326. PubMed ID: 37270803
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
    Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
    Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The promise of TRK inhibitors in pediatric cancers with NTRK fusions.
    Blauel ER; Laetsch TW
    Cancer Genet; 2022 Apr; 262-263():71-79. PubMed ID: 35108663
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of Tumor NTRK Gene Fusions to Identify Patients Who May Benefit from Tyrosine Kinase (TRK) Inhibitor Therapy.
    Hsiao SJ; Zehir A; Sireci AN; Aisner DL
    J Mol Diagn; 2019 Jul; 21(4):553-571. PubMed ID: 31075511
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.
    Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS
    Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.
    Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT
    Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
    Solomon JP; Linkov I; Rosado A; Mullaney K; Rosen EY; Frosina D; Jungbluth AA; Zehir A; Benayed R; Drilon A; Hyman DM; Ladanyi M; Sireci AN; Hechtman JF
    Mod Pathol; 2020 Jan; 33(1):38-46. PubMed ID: 31375766
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Larotrectinib efficacy and safety in adult patients with tropomyosin receptor kinase fusion sarcomas.
    Kummar S; Shen L; Hong DS; McDermott R; Keedy VL; Casanova M; Demetri GD; Dowlati A; Melcón SG; Lassen UN; Leyvraz S; Liu T; Moreno V; Patel J; Patil T; Mallick AB; Sousa N; Tahara M; Ziegler DS; Norenberg R; Arvis P; Brega N; Drilon A; Tan DSW
    Cancer; 2023 Dec; 129(23):3772-3782. PubMed ID: 37769113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of NTRK fusion detection methods in microsatellite-instability-high metastatic colorectal cancer.
    Schraa SJ; Stelloo E; Laclé MM; Swennenhuis JF; Brosens LAA; Fijneman RJA; Feitsma H; Koopman M; de Leng WW; Vink GR; Bol GM
    Virchows Arch; 2023 Jun; 482(6):983-992. PubMed ID: 37067589
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Pan-TRK Antibody is a Sensitive and Specific Tool for the Detection of NTRK Fusion Genes.
    Bautista-Wong C; Mojica-González Z; Hop-Garcia K; Bornstein Quevedo L
    Appl Immunohistochem Mol Morphol; 2023 Apr; 31(4):213-216. PubMed ID: 37017998
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characterization of an ETV6-NTRK3 rearrangement with unusual, but highly significant FISH signal pattern in a secretory carcinoma of the salivary gland: a case report.
    Wagner F; Greim R; Krebs K; Luebben F; Dimmler A
    Diagn Pathol; 2021 Aug; 16(1):73. PubMed ID: 34372873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Nefarious NTRK oncogenic fusions in pediatric sarcomas: Too many to Trk.
    Aepala MR; Peiris MN; Jiang Z; Yang W; Meyer AN; Donoghue DJ
    Cytokine Growth Factor Rev; 2022 Dec; 68():93-106. PubMed ID: 36153202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [NTRK Gene Fusions and Treatment in NTRK Fusion-Positive Solid Cancers].
    Fukuda M; Naito Y
    Gan To Kagaku Ryoho; 2022 Oct; 49(10):1048-1050. PubMed ID: 36281593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer.
    Amatu A; Sartore-Bianchi A; Bencardino K; Pizzutilo EG; Tosi F; Siena S
    Ann Oncol; 2019 Nov; 30(Suppl_8):viii5-viii15. PubMed ID: 31738427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NTRK oncogenic fusions are exclusively associated with the serrated neoplasia pathway in the colorectum and begin to occur in sessile serrated lesions.
    Kim JH; Hong JH; Choi YL; Lee JA; Seo MK; Lee MS; An SB; Sung MJ; Cho NY; Kim SS; Shin YK; Kim S; Kang GH
    J Pathol; 2021 Dec; 255(4):399-411. PubMed ID: 34402529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.